Analysts expect Ocugen to report Q2 2026 revenue of approximately $0.98 million and a loss per share of $0.05, while the current stock price of $1.27 remains well below the average analyst price target of $9.50.
Investors are primarily focused on updates regarding the company’s late-stage clinical trials and regulatory timelines for its lead gene therapy candidates.
Key areas of interest include progress on the rolling BLA submission for OCU400 for retinitis pigmentosa and clinical milestones for OCU410, which recently received FDA RMAT designation. Management is also expected to provide details on its cash runway, which was recently extended into 2028 following a $115 million private offering in May.